Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features

References

• Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer109(1), 25–32 (2007).
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology52(1), 108–118 (2008).
   PubMed Web of Science ®Google Scholar
• Lund MJ, Butler EN, Bumpers HL et al. High prevalence of triple-negative tumors in an urban cancer center. Cancer113(3), 608–615 (2008).
   PubMed Web of Science ®Google Scholar
• Dolle JM, Daling JR, White E et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol. Biomarkers Prev.18(4), 1157–1166 (2009).
   PubMed Web of Science ®Google Scholar
• Millikan RC, Newman B, Tse CK et al. Epidemiology of basal-like breast cancer. Breast Cancer Res. Treat.109(1), 123–139 (2008).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA100(14), 8418–8423 (2003).
   PubMed Web of Science ®Google Scholar
• Sorlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur. J. Cancer40(18), 2667–2675 (2004).
   PubMed Web of Science ®Google Scholar
• Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology41(1), 40–47 (2009).
   PubMed Web of Science ®Google Scholar
• Chivukula M, Striebel JM, Ersahin C, Dabbs DJ. Evaluation of morphologic features to identify “basal-like phenotype” on core needle biopsies of breast. Appl. Immunohistochem. Mol. Morphol.16(5), 411–416 (2008).
   Google Scholar
• Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol.19(2), 264–271 (2006).
   PubMed Web of Science ®Google Scholar
• Kreike B, Van Kouwenhove M, Horlings H et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res.9(5), R65 (2007).
   PubMed Web of Science ®Google Scholar
• Arnes JB, Brunet JS, Stefansson I et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin. Cancer Res.11(11), 4003–4011 (2005).
   PubMed Web of Science ®Google Scholar
• Bori R, Cserni G. Basal phenotype in breast carcinoma occurring in women aged 35 or younger. Pathol. Oncol. Res.15(1), 41–45 (2009).
   Google Scholar
• Lerma E, Peiro G, Ramon T et al. Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and HER2/neu (basal-like breast carcinomas). Mod. Pathol.20(11), 1200–1207 (2007).
   Google Scholar
• Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial–mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res.68(4), 989–997 (2008).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98(19), 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res.10(16), 5367–5374 (2004).
   PubMed Web of Science ®Google Scholar
• Elsheikh SE, Green AR, Rakha EA et al. Caveolin 1 and caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br. J. Cancer99(2), 327–334 (2008).
   PubMed Web of Science ®Google Scholar
• Gauthier ML, Berman HK, Miller C et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell12(5), 479–491 (2007).
   PubMed Web of Science ®Google Scholar
• Tan DS, Marchio C, Jones RL et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res. Treat.111(1), 27–44 (2008).
   PubMed Web of Science ®Google Scholar
• Toyama T, Yamashita H, Kondo N et al. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer8, 309 (2008).
   PubMed Web of Science ®Google Scholar
• Viale G, Rotmensz N, Maisonneuve P et al. Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res. Treat.116(2), 317–328 (2009).
   PubMed Web of Science ®Google Scholar
• Bhargava R, Gerald WL, Li AR et al.EGFR gene amplification in breast cancer: Correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod. Pathol.18(8), 1027–1033 (2005).
   PubMedGoogle Scholar
• Andre F, Job B, Dessen P et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin. Cancer Res.15(2), 441–451 (2009).
   PubMed Web of Science ®Google Scholar
• Bertucci F, Finetti P, Cervera N et al. How basal are triple-negative breast cancers?. Int. J. Cancer123(1), 236–240 (2008).
   PubMed Web of Science ®Google Scholar
• Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res.14(5), 1368–1376 (2008).
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Milanezi F, Steele D et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology49(1), 10–21 (2006).
   PubMed Web of Science ®Google Scholar
• Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod. Pathol.19(5), 617–621 (2006).
   PubMedGoogle Scholar
• Paredes J, Lopes N, Milanezi F, Schmitt FC. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch.450(1), 73–80 (2007).
   PubMedGoogle Scholar
• Dabbs DJ, Chivukula M, Carter G, Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod. Pathol.19(11), 1506–1511 (2006).
   Google Scholar
• Honrado E, Benitez J, Palacios J. Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit. Rev. Oncol. Hematol.59(1), 27–39 (2006).
   PubMedGoogle Scholar
• Lakhani SR, Reis-Filho JS, Fulford L et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res.11(14), 5175–5180 (2005).
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Stefansson IM, Chappuis PO et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst.95(19), 1482–1485 (2003).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Pinilla SM, Sarrio D, Honrado E et al. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J. Clin. Pathol.60(9), 1006–1012 (2007).
   PubMed Web of Science ®Google Scholar
• Turner NC, Reis-Filho JS, Russell AM et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene26(14), 2126–2132 (2007).
   PubMed Web of Science ®Google Scholar
• Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene25(43), 5846–5853 (2006).
   PubMed Web of Science ®Google Scholar
• Atchley DP, Albarracin CT, Lopez A et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J. Clin. Oncol.26(26), 4282–4288 (2008).
   PubMed Web of Science ®Google Scholar
• Luck AA, Evans AJ, James JJ et al. Breast carcinoma with basal phenotype: mammographic findings. AJR Am. J. Roentgenol.191(2), 346–351 (2008).
   Google Scholar
• Yang WT, Dryden M, Broglio K et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res. Treat.111(3), 405–410 (2008).
   Google Scholar
• Collett K, Stefansson IM, Eide J et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol. Biomarkers Prev.14(5), 1108–1112 (2005).
   PubMed Web of Science ®Google Scholar
• Chen JH, Mehta RS, Carpenter PM, Nalcioglu O, Su MY. Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy. J. Clin. Oncol.25(35), 5667–5669 (2007).
   Google Scholar
• Uematsu T, Kasami M, Yuen S. Triple-negative breast cancer: correlation between MR imaging and pathologic findings. Radiology250(3), 638–647 (2009).
   Google Scholar
• Basu S, Chen W, Tchou J et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer112(5), 995–1000 (2008).
   Google Scholar
• Gerson R, Alban F, Villalobos A, Serrano A. [Recurrence and survival rates among early breast cancer cases with triple negative immunophenotype]. Gac. Med. Mex.144(1), 27–34 (2008).
   Google Scholar
• Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer?. Breast Cancer15(4), 303–308 (2008).
   Google Scholar
• Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol.24(36), 5652–5657 (2006).
   PubMed Web of Science ®Google Scholar
• Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res. Treat.115(2), 423–428 (2009).
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res.13(15 Pt 1), 4429–4434 (2007).
   PubMed Web of Science ®Google Scholar
• Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res. Treat.115(2), 423–428 (2009).
   PubMed Web of Science ®Google Scholar
• Evans AJ, Rakha EA, Pinder SE, Green AR, Paish C, Ellis IO. Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. J. Med. Screen.14(4), 210–214 (2007).
   Google Scholar
• Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer109(9), 1721–1728 (2007).
   PubMed Web of Science ®Google Scholar
• Rakha EA, El-Rehim DA, Paish C et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur. J. Cancer42(18), 3149–3156 (2006).
   PubMed Web of Science ®Google Scholar
• Mulligan AM, Pinnaduwage D, Bull SB, O’Malley FP, Andrulis IL. Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort. Clin. Cancer Res.14(13), 4168–4174 (2008).
   PubMed Web of Science ®Google Scholar
• Tischkowitz M, Brunet JS, Begin LR et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer7, 134 (2007).
   PubMed Web of Science ®Google Scholar
• Nofech-Mozes S, Trudeau M, Kahn HK et al. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. Breast Cancer Res. Treat.118(1), 131–137 (2009).
   PubMedGoogle Scholar
• Nogi H, Kobayashi T, Suzuki M et al. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncol. Rep.21(2), 413–417 (2009).
   PubMed Web of Science ®Google Scholar
• Fulford LG, Reis-Filho JS, Ryder K et al. Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res.9(1), R4 (2007).
   PubMed Web of Science ®Google Scholar
• Crabb SJ, Cheang MC, Leung S et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin. Breast Cancer8(3), 249–256 (2008).
   Google Scholar
• Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol.26(8), 1275–1281 (2008).
   PubMed Web of Science ®Google Scholar
• Luck AA, Evans AJ, Green AR, Rakha EA, Paish C, Ellis IO. The influence of basal phenotype on the metastatic pattern of breast cancer. Clin. Oncol. (R. Coll. Radiol.)20(1), 40–45 (2008).
   PubMed Web of Science ®Google Scholar
• Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer113(10), 2638–2645 (2008).
   PubMed Web of Science ®Google Scholar
• Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann. Oncol.19(9), 1561–1565 (2008).
   PubMedGoogle Scholar
• Miyoshi Y, Murase K, Oh K. Basal-like subtype and BRCA1 dysfunction in breast cancers. Int. J. Clin. Oncol.13(5), 395–400 (2008).
   PubMed Web of Science ®Google Scholar
• Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res.13(8), 2329–2334 (2007).
   PubMed Web of Science ®Google Scholar
• Gilmore PM, McCabe N, Quinn JE et al. BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3. Cancer Res.64(12), 4148–4154 (2004).
   Google Scholar
• Harris LN, Broadwater G, Lin NU et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res.8(6), R66 (2006).
   PubMed Web of Science ®Google Scholar
• Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res.11(16), 5678–5685 (2005).
   PubMed Web of Science ®Google Scholar
• Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, Robert J. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res.64(1), 356–362 (2004).
   PubMed Web of Science ®Google Scholar
• Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J. Clin. Invest.117(5), 1370–1380 (2007).
   PubMed Web of Science ®Google Scholar
• Sirohi B, Arnedos M, Popat S et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann. Oncol.19(11), 1847–1852 (2008).
   PubMed Web of Science ®Google Scholar
• Torrisi R, Balduzzi A, Ghisini R et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother. Pharmacol.62(4), 667–672 (2008).
   PubMed Web of Science ®Google Scholar
• Byrski T, Gronwald J, Huzarski T et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res. Treat.108(2), 289–296 (2008).
   PubMed Web of Science ®Google Scholar
• Hayes DF, Thor AD, Dressler LG et al. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med.357(15), 1496–1506 (2007).
   PubMed Web of Science ®Google Scholar
• Gluz O, Nitz UA, Harbeck N et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann. Oncol.19(5), 861–870 (2008).
   PubMed Web of Science ®Google Scholar
• Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial c9741/Cancer and Leukemia Group B trial 9741. J. Clin. Oncol.21(8), 1431–1439 (2003).
   PubMed Web of Science ®Google Scholar
• Diallo-Danebrock R, Ting E, Gluz O et al. Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin. Cancer Res.13(2 Pt 1), 488–497 (2007).
   PubMed Web of Science ®Google Scholar
• Nieto Y, Shpall EJ. High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?. Curr. Opin. Oncol.21(2), 150–157 (2009).
   PubMed Web of Science ®Google Scholar
• Tan AR, Swain SM. Therapeutic strategies for triple-negative breast cancer. Cancer J.14(6), 343–351 (2008).
   Web of Science ®Google Scholar
• Corkery B, Crown J, Clynes M, O’Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann. Oncol. (2009).
   PubMedGoogle Scholar
• Oliveras-Ferraros C, Vazquez-Martin A, Lopez-Bonet E et al. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Int. J. Oncol.33(6), 1165–1176 (2008).
   PubMed Web of Science ®Google Scholar
• Bouchalova K, Cizkova M, Cwiertka K, Trojanec R, Hajduch M. Triple negative breast cancer – current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and c-Myc gene assessment. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech Repub.153(1), 13–17 (2009).
   Google Scholar
• Ribeiro-Silva A, Ribeiro Do Vale F, Zucoloto S. Vascular endothelial growth factor expression in the basal subtype of breast carcinoma. Am. J. Clin. Pathol.125(4), 512–518 (2006).
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med.357(26), 2666–2676 (2007).
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Elias AD, Rugo HS et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol.26(11), 1810–1816 (2008).
   PubMed Web of Science ®Google Scholar
• Rottenberg S, Jaspers JE, Kersbergen A et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor Azd2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA105(44), 17079–17084 (2008).
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med.361(2), 123–134 (2009).
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy JOC, Pippen J. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC). J. Clin. Oncol.27(Suppl. 18), (2009) (Abstract 3).
   Google Scholar
• Dizdar O, Dede DS, Bulut N, Altundag K. Dasatinib may also inhibit c-kit in triple negative breast cancer cell lines. Breast Cancer Res. Treat.107(2), 303 (2008).
   PubMedGoogle Scholar
• Finn RS. Targeting src in breast cancer. Ann. Oncol.19(8), 1379–1386 (2008).
   PubMed Web of Science ®Google Scholar
• Huang F, Reeves K, Han X et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res.67(5), 2226–2238 (2007).
   PubMed Web of Science ®Google Scholar
• Chen Y, Olopade OI. Myc in breast tumor progression. Expert Rev. Anticancer Ther.8(10), 1689–1698 (2008).
   PubMed Web of Science ®Google Scholar
• Kurebayashi J. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics. Breast Cancer16(4), 275–280 (2009).
   Google Scholar
• Yuli C, Shao N, Rao R et al. BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers. Oncogene26(41), 6031–6037 (2007).
   PubMed Web of Science ®Google Scholar
• Rahman M, Davis SR, Pumphrey JG et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res. Treat.113(2), 217–230 (2009).
   PubMed Web of Science ®Google Scholar